Intellia Therapeutics Inc has announced gross proceeds of about $600 million from a public offering of its shares on the US Nasdaq market. The offering consisted of 4.1 million shares which were priced at $145 per share on 29 June. The underwriters have also been granted a 30-day option to buy additional stock.
